ArticleScientific reports2025
Engineering filamentous potato virus X as a platform nanotechnology for nucleic acid gene delivery.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Assembly of the Linear Viral Nucleocapsid.Microorganisms · 2026Article
- Virus-like particles based on plant viruses and bacteriophages: emerging strategies for the delivery of nucleic acid therapeutics.Chemical science · 2026Review
- Strategies for controlled assembly of rod-shaped viral particles.Biotechnology advancesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Nucleic acid therapeutics and gene delivery platforms have the potential to change the way we treat disease, enabling precision medicine. Advances in biotechnology have allowed for production of virtually any functional protein or peptide in the human body through the introduction of various classes of RNA, including regulatory and coding RNAs (e.g., mRNA) in the form of linear or circular RNA (circRNA). To be effective, nucleic acid therapeutics require safe, stable, and efficient delivery vehicles that protect the otherwise labile cargo from degradation, promote cellular uptake, and facilitate payload release. Lipid nanoparticles (LNPs) have enjoyed recent clinical success for the delivery of mRNA to combat disease - especially against coronavirus 2019 (SARS CoV-2) and, more recently, against high-grade ductal breast carcinoma (clinical trial) - marking significant milestones for RNA nanomedicines. As an alternative to LNPs and mammalian viral vectors, we report the use of nucleoprotein components from a filamentous plant virus, potato virus X (PVX) as an RNA platform delivery technology. Designer nucleoprotein complexes of filamentous and halo-shaped nanoparticles were obtained through self-assembled templating on custom mRNAs and circRNAs. The flexuous nature of the PVX platform enabled the packing of circRNA yielding a unique nanoparticle platform. We explored assembly from coat protein (CP) obtained from PVX particles produced in planta but also extended the design space by producing recombinant CP by bacterial expression. Controlled mixed assemblies were achieved allowing the programming of mosaic particles with integrated functionality; length control was also demonstrated, resulting in bespoke nucleic acid delivery vehicles for tunable pharmacology. Using reporter genes, we demonstrate successful transfection of eukaryotic cells and target protein expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.